Alzamend Neuro

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). The company's mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Their current pipeline consists of two novel therapeutic drug candidates: AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Founded in 2016, Alzamend Neuro operates in the Biotechnology and Health Care industries, with its headquarters in the United States. The company received a $25.00M Post-IPO Equity investment on 09 May 2024. As a promising player in the field of neurobiological therapeutics, Alzamend Neuro shows potential in addressing the unmet medical needs in treating Alzheimer's disease, Bipolar Disorder, MDD, and PTSD. With a focus on pioneering treatments and a solid investment backing, it holds promise for making significant strides in addressing these pressing health challenges.